XNYS · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 2 Form 144 pre-sale notices filed on 2026-05-29. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-27. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-18. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one …
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-12. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one …
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-22. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Edwards Lifesciences (EW) had 1 Form 144 pre-sale notice filed on 2026-05-15. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Edwards Lifesciences reported Q1 2026 total sales of $1.65 billion, with its flagship TAVR segment growing 14.4% to $1.2 billion and EPS of $0.66 — strong enough that management raised full-year guidance immediate…
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 6/30/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | -619 | — | — |
| 6/30/2026 | Lippis Daniel J. | CVP, TAVR | SELL | -619 | $91 | $56,577 |
| 6/30/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | 619 | $73 | $44,989 |
| 6/17/2026 | Zovighian Bernard J | CEO | SELL | -523 | $88 | $45,982 |
| 5/29/2026 | Dahl Andrew M. | SVP, Corporate Controller | SELL | -567.53 | $86 | $48,853 |
| 5/27/2026 | BOBO DONALD E JR | CVP,Strategy/Corp Development | SELL | -23,145 | $86 | $2,000,193 |
| 5/22/2026 | Chopra Daveen | CVP, TMTT & Surgical | SELL | -1,500 | $85 | $126,905 |
| 5/18/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | -620 | — | — |
| 5/18/2026 | Lippis Daniel J. | CVP, TAVR | SELL | -620 | $81 | $50,307 |
| 5/18/2026 | Lippis Daniel J. | CVP, TAVR | OPTION_EXERCISE | 620 | $73 | $45,062 |
| 5/15/2026 | BOBO DONALD E JR | CVP,Strategy/Corp Development | SELL | -8,000 | $82 | $654,573 |
| 5/15/2026 | BOBO DONALD E JR | CVP,Strategy/Corp Development | SELL | -9,968 | $82 | $818,106 |
| 5/12/2026 | Zovighian Bernard J | CEO | GIFT | -26,640 | — | — |
| 5/12/2026 | Zovighian Bernard J | CEO | GIFT | 26,640 | — | — |
| 5/12/2026 | Zovighian Bernard J | CEO | SELL | -845 | $78 | $66,250 |
| 5/12/2026 | Zovighian Bernard J | CEO | SELL | -35,506 | $78 | $2,766,762 |
| 5/11/2026 | Ullem Scott B. | CVP, Chief Financial Officer | OPTION_EXERCISE | 19,830 | — | — |
| 5/11/2026 | Ullem Scott B. | CVP, Chief Financial Officer | TAX_WITHHOLD | -11,004 | $80 | $879,880 |
| 5/11/2026 | Ullem Scott B. | CVP, Chief Financial Officer | OPTION_EXERCISE | -19,830 | — | — |
| 5/11/2026 | Markowitz Wayne | CVP, JAPAC | SELL | -593 | $80 | $47,280 |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| 5/29/2026 | Ullem Scott B. | — | 64,152 | SEC |
| 5/29/2026 | Dahl Andrew M. | — | 568 | SEC |
| 5/27/2026 | BOBO JR FAMILY TRUST | — | 23,145 | SEC |
| 5/22/2026 | Chopra Daveen | — | 1,500 | SEC |
| 5/18/2026 | Lippis Daniel J. | — | 1,858 | SEC |
| 5/15/2026 | BOBO DONALD E JR | — | 9,968 | SEC |
| 5/12/2026 | Zovighian Bernard J | — | 36,874 | SEC |
| 5/11/2026 | Markowitz Wayne | — | 593 | SEC |
| 5/4/2026 | Lippis Daniel J. | — | 1,019 | SEC |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| 6/1/2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 70,079,435 | $5,974,271,834 | — | 1/29/2026 |
| BlackRock | 50,975,492 | $4,708,606,210 | — | 8/13/2024 |
| JP Morgan Chase | 26,349,452 | $2,246,290,811 | — | 2/11/2026 |
| State Street | 25,991,524 | $2,215,777,421 | — | 2/13/2026 |
| Fidelity (FMR) | 16,582,547 | $1,413,662,134 | — | 2/17/2026 |
| Millennium Management | 6,502,638 | $554,349,889 | — | 2/17/2026 |
| Citadel Advisors | 2,550,027 | $217,389,802 | — | 2/17/2026 |
| AQR Capital | 2,241,751 | $191,109,205 | — | 2/17/2026 |
| Point72 | 478,767 | $40,814,887 | — | 2/17/2026 |
| Two Sigma | 391,386 | $33,365,657 | — | 2/17/2026 |
| DE Shaw | 89,515 | $7,631,154 | — | 2/17/2026 |
| Bridgewater Associates | 76,762 | $6,543,960 | — | 2/13/2026 |